CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC co-op takes engineering student from bartending to Buffalo Trace
July 31, 2026
Student bartender Brady Billhorn takes part in cooperative education, or co-op, as part of his mechanical engineering technology degree program. His most recent co-op took him behind the scenes at Buffalo Trace Distillery.
UC Klekamp Law and the University of Lima (Peru) sign agreement to expand global legal education
July 31, 2026
The University of Cincinnati Klekamp College of Law signs collaboration agreement with University of Lima (Peru) for LLM students.
CCM hosts Conducting Symposium on Nov. 12-14
July 31, 2026
UC's College-Conservatory of Music hosts the CCM Wind Conducting Symposium on Nov. 12-14, 2026. Open to emerging and established conductors, participants will have the opportunity to conduct CCM ensembles and receive instruction and feedback from CCM Wind Studies faculty Kevin Holzman and Tyler Ehrlich, as well as guest artist/ clinician Jerry Junkin, Director of Bands at The University of Texas at Austin.